Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ESPR Relative to the S&P 500

ESPR Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Esperion Therapeutics, Inc. (NASD:ESPR) seasonal charts above shows that a Buy Date of August 20 and a Sell Date of December 5 has resulted in a geometric average return of 5.85% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 27.06% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

To download ESPR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ESPR